Chronic Fatigue Immune Dysfunction Syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating long-term medical condition. People with ME/CFS experience lengthy flare-ups of the illness following relatively minor physical or mental activity. This is known as post-exertional malaise (PEM) and is the hallmark symptom of the illness. Other core symptoms are a greatly reduced ability to do tasks that were previously routine, severe fatigue, and sleep disturbances. The baseline fatigue in ME/CFS does not improve much with rest. Orthostatic intolerance, memory and concentration problems, and chronic pain are common. ME/CFS negatively impacts people's health and abilities and can cause social isolation. About a quarter of the people are severely affected and unable to leave their bed or home.

The root cause(s) of the disease are unknown and the mechanisms are not fully understood. ME/CFS often starts after a flu-like infection, for instance after infectious mononucleosis. In some people, physical trauma or psychological stress may also act as a trigger. A genetic component is suspected, as ME/CFS can run in families. ME/CFS is associated with changes in the nervous and immune system, energy metabolism and hormone production. Diagnosis is based on symptoms because no confirmed diagnostic test is available.

The illness may unpredictably improve, worsen, or fluctuate in severity, but full recovery is rare. Treatment is aimed at relieving symptoms, as no therapies or medications are approved to treat the condition. Pacing and activity management can help prevent flare-ups and counseling may aid in coping with the illness. About 1% of people have ME/CFS and estimates vary widely because studies use different definitions. ME/CFS occurs 1.5 to 2 times as often in women as in men. It most commonly affects adults between the ages of 40 and 60, but can occur at other ages, including childhood.

There has been controversy over many aspects of the condition, including the cause and potential treatments, and historical research funding for ME/CFS has been far below that of comparable diseases. People with ME/CFS often face stigma in healthcare settings, and doctors may have difficulty managing an illness that lacks a clear understanding.

Classification

ME/CFS has been classified as neurological disease by the World Health Organization (WHO) since 1969, initially under the name ''benign myalgic encephalomyelitis.'' Even though the cause of the illness is unknown, symptoms point to a central role of the nervous system. Alternatively, based on abnormalities of immune cells, it has been classified as a neuroimmune condition.

In the WHO's most recent classification, ICD-11, both chronic fatigue syndrome and myalgic encephalomyelitis are listed under the term ''post-viral fatigue syndrome.'' They are classified as ''other disorders of the nervous system''. In the ICD-10, only (benign) ME was listed, and there was no mention of CFS. Clinicians often used diagnostic codes for fatigue and malaise, or fatigue syndrome for people with CFS.

Signs and symptoms

The United States Centers for Disease Control and Prevention (CDC) recommends these criteria for diagnosis:
* Greatly lowered ability to do activities that were usual before the illness. This drop in activity level occurs along with fatigue and must last six months or longer.
* Worsening of symptoms after physical or mental activity that would not have caused a problem before the illness. The amount of activity that might aggravate the illness is difficult for a person to predict, and the decline often presents 12 to 48 hours after the activity. The 'relapse', or 'crash', may last days, weeks or longer. This is known as post-exertional malaise (PEM).
* Sleep problems; people may still feel weary after full nights of sleep, or may struggle to stay awake, fall asleep or stay asleep.

Additionally, one of the following symptoms must be present:
* Problems with thinking and memory (cognitive dysfunction, sometimes described as "brain fog")
* While standing or sitting upright; lightheadedness, dizziness, weakness, fainting or vision changes may occur ( orthostatic intolerance)

Debilitating fatigue

People with ME/CFS experience a debilitating fatigue, which is made worse by activity, not caused by cognitive, physical, social or emotional overexertion, and minimally alleviated by rest. Particularly in the initial period of illness, this fatigue is described as "flu-like". People with ME/CFS may feel restless, and describe their experience as "wired but tired". When starting an activity, muscle strength may drop rapidly, which can lead to sudden weakness, difficulty with coordination and clumsiness.

Post-exertional malaise

The hallmark feature of ME/CFS is a worsening of symptoms after activity. This is called post-exertional malaise (PEM) or more accurately post-exertional symptom exacerbation. The term malaise may be considered outdated, as it gives the impression of a "vague discomfort". PEM involves increased fatigue and functional limitations. It can also include heightened flu-like symptoms, pain, cognitive difficulties, gastrointestinal issues, nausea or sleep disturbances. The crash can lasts hours, days, weeks or months. Extended durations of PEM are frequently denoted as 'crashes' or flare-ups among individuals with ME/CFS and might foreshadow a prolonged relapse.

All types of activities that require energy can trigger PEM. It can be physical or cognitive, but also social or emotional. The amount of activity that might aggravate the illness is difficult for a person to predict and the decline often presents 12 to 48 hours after the activity, but exacerbation can also start immediately after activity.

Sleep problems

There is a wide variety of sleep problems in the ME/CFS population. Sleep is often described as unrefreshing: People wake up exhausted and stiff rather than restored after a night's sleep. This can be caused by a reversed cycle of wakefulness and sleep, shallow sleep or broken sleep. However, even a full night sleep is typically non-restorative. Some people with ME/CFS experience insomnia, hypersomnia (excessive sleepiness) or vivid nightmares. Sleep apnoea may be present as a co-occurring condition. However, many diagnostic criteria state that sleep disorders must be excluded before a diagnosis of ME/CFS is confirmed.

Cognitive dysfunction

Cognitive dysfunction is one of the most disabling aspects of CFS due to its negative impact on occupational and social functioning. 50–80% of people with CFS are estimated to have serious problems with cognition. Cognitive symptoms are mainly due to deficits in attention, memory, and reaction time. Measured cognitive abilities are found to be below projected normal values and likely to affect day-to-day activities, causing increases in common mistakes, forgetting scheduled tasks, or having difficulty responding when spoken to.

Simple and complex information-processing speed and functions entailing working memory over long time periods are moderately to extensively impaired. These deficits are generally consistent with the patient's perceptions. Perceptual abilities, motor speed, language, reasoning, and intelligence do not appear to be significantly altered. Patients who report poorer health status tend to also report more severe cognitive trouble, and better physical functioning is associated with less visuoperceptual difficulty and fewer language-processing complaints.

Orthostatic intolerance

People with ME/CFS often experience orthostatic intolerance, symptoms that start or worsen with standing or sitting. Symptoms, which include nausea, lightheadedness and cognitive impairment, often improve again after lying down. Postural orthostatic tachycardia syndrome (POTS), an excessive increase in heart rate after standing up, is the most common form of orthostatic intolerance in ME/CFS. Sometimes, POTS can result in fainting. Orthostatic hypotension, a drop in blood pressure after standing, may also be present.

Other common symptoms

Pain and hyperalgesia (an abnormally increased sensitivity to pain) are common in ME/CFS. The pain is not accompanied by swelling or redness. The pain can be present in muscles (as myalgia) and joints, in the lymph nodes and as a sore throat. Chronic pain behind the eyes and in the neck and neuropathic pain (related to disorders of the nervous system) is also described. Headaches and migraines that were not present before the illness can be present as well. However, chronic daily headaches may indicate an alternative diagnosis. PEM frequently makes pain worse; Normally, exercise has the opposite effect, making people less sensitive to pain.

Many, but not all people with ME/CFS further report:
* Irritable bowel syndrome
* Chills and night sweats
* Allergies and sensitivities to foods, odors, chemicals, lights, or noise
* Shortness of breath
* Irregular heartbeat

Onset

The onset of ME/CFS may be gradual or sudden. When it begins suddenly, it often follows an episode of infectious-like symptoms or a known infection, and between 25% and 80% report an infectious-like onset. When gradual, the illness may begin over the course of months or years with no apparent trigger. It is also frequent for ME/CFS to begin with multiple triggering events that initially cause minor symptoms and culminate in a final trigger leading to a noticeable onset. Studies disagree as whether sudden or gradual onset is more common. ME/CFS may also occur after physical trauma such as a car accident or surgery.

Severity

ME/CFS often causes significant disability, but the degree varies greatly. People with ME/CFS can be divided into four categories of illness severity:

* People with mild ME/CFS can usually still work and care for themselves, but will need their free time to recover from these activities, rather than engaging in social and leisure activities
* Moderate severity results in a large reduction in activities of daily living (self-care activities, such as feeding and washing oneself). People are usually unable to work and require frequent resting.
* People with severe ME/CFS are homebound and can do only limited activities of daily living.
* In the very severe group, people are mostly bedbound and cannot independently care for themselves.

Roughly a quarter of people with ME/CFS fall in the mild category, half in the moderate or moderate-to-severe category. The final quarter fall in the severe or very severe category. Severity may change over time, with periods of worsening, improvement or remission sometimes occurring. Persons who feel better for a period may overextend their activities, triggering post-exertional malaise and a worsening of symptoms.

People with severe and very severe ME/CFS experience more or more severe symptoms. They may face severe weakness and may be unable to move at times. They can lose the ability to speak or swallow, or lose the ability to communicate completely due to cognitive issues. They can further experience hypersensitivities to touch, light, sound, and smells, and experience severe pain. The activities that can trigger post-exertional malaise in these patients are very minor, such as sitting or going to the toilet.

People with ME/CFS have decreased quality of life according to the SF-36 questionnaire, especially in the domains of vitality, physical functioning, general health, physical role, and social functioning. However, their scores in the "role emotional" and mental health domains were not substantially lower than healthy controls. A 2015 study found that people with ME/CFS had lower health-related quality of life than 20 other medical conditions, including multiple sclerosis, kidney failure, and lung cancer.

Cause

The cause of ME/CFS is unknown. Both genetic and environmental factors are believed to contribute, but the genetic component is unlikely to be a single gene. Problems with the nervous and immune systems, and energy metabolism, may be factors. ME/CFS is a biological disease, not a psychiatric or psychological condition, and is not caused by deconditioning.

Because the illness often follows a known or apparent viral illness, various infectious agents have been proposed, but a single cause has not been found. For instance, ME/CFS may start after mononucleosis, a H1N1 influenza infection, a varicella zoster virus infection (the virus that causes chickenpox), SARS-CoV-1 or SARS-CoV-2.

Risk factors

All ages, ethnic groups, and income levels are susceptible to the illness. The CDC states that while Caucasians may be diagnosed more frequently than other races in America, the illness is at least as prevalent among African Americans and Hispanics. A 2009 meta-analysis found that Asian Americans have a lower risk of CFS than White Americans, while Native Americans have a higher (probably a much higher) risk and African Americans probably have a higher risk. The review acknowledged that studies and data were limited.

More women than men get ME/CFS. A large 2020 meta-analysis estimated that between 1.5 and 2.0 times more cases are women. The review noted that different case definitions and diagnostic methods within datasets yielded a wide range of prevalence rates. The CDC estimates ME/CFS occurs up to four times more often in women than in men. The illness can occur at any age, but has the highest prevalence in people aged 40 to 60. ME/CFS is less prevalent among children and adolescents than among adults.

People with affected relatives appear to be more likely to get ME/CFS, implying the existence of genetic risk factors. People with a family history of neurological or autoimmune diseases are also at increased risk. Results of genetic studies have been largely contradictory or unreplicated. One study found an association with mildly deleterious mitochondrial DNA variants, and another found an association with certain variants of human leukocyte antigen genes.

Viral and other infections

Viral infections have long been suspected to cause ME/CFS, based on the observation ME/CFS sometimes occurs in outbreaks and is connected to autoimmune diseases. How viral infections cause ME/CFS is unclear: it could be via viral persistence, or via a "hit and run" mechanism, in which infections dysregulate the immune system or cause autoimmunity.

Different types of viral infection have been implicated in ME/CFS, including airway infections, bronchitis, gastroenteritis, or an acute "flu-like illness". A meta-analysis of different viral infections identified the borna disease virus as having the highest odds of causing ME/CFS. Six other viral infections were also identified with a weaker link to ME/CFS. The analysis did not include COVID-19. Between 15% to 50% of people with long COVID also meet the diagnostic criteria for ME/CFS.

Reactivation of latent viruses have also been hypothesized to drive symptoms, in particular Epstein-Barr virus (EBV). EBV is present in about 90% of people, usually in a latent state. EBV antibody activity is often higher in people with ME/CFS, indicating reactivation. Of people who get infection mononucleosis, which is triggered by EBV, around 8% to 15% develop ME/CFS, depending on criteria.

A systematic review found that fatigue severity was the main predictor of prognosis in CFS, and did not identify psychological factors linked to prognosis. Another review found that risk factors for developing post-viral fatigue or CFS after mononucleosis, dengue fever, or Q-fever included longer bed-rest during the illness, poorer pre-illness physical fitness, attributing symptoms to physical illness, belief that a long recovery time is needed, as well as pre-infection distress and fatigue. The same review found biological factors such as CD4 and CD8 activation and liver inflammation are predictors of sub-acute fatigue but not CFS.

Pathophysiology

ME/CFS is associated with changes in several areas, including the nervous, immune, and endocrine systems. Reported neurological differences include altered brain structure and metabolism, and autonomic nervous system dysfunction. Observed immunological changes include decreased natural killer cell activity, increased cytokines. Endocrine differences, such as modestly low cortisol and HPA axis dysregulation, have been noted as well. Impaired energy production and the possibility of autoimmunity are other areas of interest.

Neurological

A range of structural, biochemical and functional abnormalities is found brain imaging studies in people with ME/CFS. A consistent and frequent finding is the recruitment of additional brain areas in cognitive tasks. Other consistent findings, but based on a low number of studies, are regional hypometabolism, reduced serotonin transporters and problems with neurovascular coupling.
Neuroinflammation has been proposed as an underlying mechanism of ME/CFS that could explain a large set of symptoms. A number of studies suggest neuroinflammatory abnormalities in the cortical and limbic regions of the brain in people with ME/CFS. People with ME/CFS for instance have higher brain lactate and choline levels, which point to neuroinflammation. Two small PET studies of microglia, a type of immune cell in the brain, were contradictory however. However, methodological problems and lack of replication mean that further research is necessary, and direct evidence for nervous system inflammation is somewhat limited.

ME/CFS affects sleep. People with ME/CFS experience decreased sleep efficiency, take longer to fall asleep and longer to achieve REM sleep. Changes to non-REM sleep have also been found, together suggesting a role of the autonomic nervous system. People with ME/CFS often have an abnormal heart rate response to a tilt table test, in which a patient is moved from a flat to an upright position. This again suggests dysfunction in the autonomic nervous system.

Immunological

People with ME/CFS often have immunological abnormalities. A consistent finding in studies is a decreased activity of natural killer cells, a type of immune cell that targets virus-infected and tumour cells. People with ME/CFS have an abnormal response to exercise, including increased production of complement products, increased oxidative stress combined with decreased antioxidant response, and increased interleukin 10, and TLR4, some of which correlates with symptom severity. Increased levels of cytokines have been proposed to account for the decreased ATP production and increased lactate during exercise; however, the elevations of cytokine levels are inconsistent in specific cytokine, albeit frequently found.

Autoimmunity has been proposed to be a factor in ME/CFS. There is a subset of people with ME with increased B cell activity and autoantibodies, possibly as a result of decreased NK cell regulation or viral mimicry. In 2015, a large German study found 29% of people with ME/CFS had elevated autoantibodies to M3 and M4 muscarinic acetylcholine receptors as well as to ß2 adrenergic receptors. Problems with these receptors can lead to impaired blood flow.

Energy metabolism

Objective signs of PEM have been found with the 2-day CPET, a test that involves taking VO₂max tests on successive days. People with ME/CFS have lower performance and heart rate compared to healthy controls on the first test. On the second test, healthy people's scores stay the same or increase slightly, while people with ME/CFS have a decrease in anaerobic threshold, peak power output, and VO₂max. Potential causes include impaired oxygen transport, impaired aerobic metabolism, and mitochondrial dysfunction.

Studies have observed mitochondrial abnormalities in cellular energy production, but heterogeneity among studies make it difficult to draw any conclusions. ME/CFS is likely not a mainly mitochondrial disorder, based on genetic evidence. An example of a possible mitochondrial mechanism in ME/CFS is the overexpression of the WASF3 protein, which reduced mitochrondrial supercomplex formation and thereby cellular energy production.

Other

Evidence points to abnormalities in the hypothalamic-pituitary-adrenal axis (HPA axis) in some people with ME/CFS, which may include lower cortisol levels, a decrease in the variation of cortisol levels throughout the day and decreased responsiveness of the HPA axis. This can be considered to be a "HPA axis phenotype" that is also present in some other conditions, including post-traumatic stress disorder and some autoimmune conditions. In most healthy adults, the cortisol awakening response shows an increase in cortisol levels averaging 50% in the first half-hour after waking. In people with CFS, this increase apparently is significantly less, but methods of measuring cortisol levels vary, so this is not certain.

Other abnormalities have been proposed are reduced blood flow to the brain under orthostatic stress (as found in a tilt table test), small-fibre neuropathy, and an increase in the amount of gut microbes entering the blood.

Diagnosis

Diagnosis of ME/CFS is based on symptoms. No characteristic laboratory abnormalities are approved for diagnosis; while physical abnormalities can be found, no single finding is considered sufficient for diagnosis. Blood, urine, and other tests are used to rule out other conditions that could be responsible for the symptoms. A diagnosis may further include taking a medical history and a mental and physical examination. People with ME/CFS often face significant delays in diagnosis.

Diagnostic tools

The CDC recommends considering the questionnaires and tools described in the 2015 Institute of Medicine report, which include:
* DePaul Symptom Questionnaire
* CDC Symptom Inventory for CFS
* The Chalder Fatigue Scale
* The Krupp Fatigue Severity Scale
* Work and Social Adjustment Scale (WSAS)
* SF-36 / RAND-36
* Pittsburgh Sleep Quality Index (PSQI)

A two-day cardiopulmonary exercise test (CPET) is not necessary for diagnosis, although lower readings on the second day may be helpful in supporting a claim for Social Security disability. A two-day CPET cannot be used to rule out ME/CFS. Orthostatic intolerance can be measured with a tilt table test, or if that is unavaible, using the simpler NASA 10-minute lean test.

Definitions

Multiple research and clinical criteria exist to diagnose ME/CFS. These include the NICE guidelines, IOM criteria, the International Consensus Criteria (ICC), the Canadian Consensus Criteria (CCC), and CDC criteria. The criteria sets were all developed based on expert consensus, and differ in the required symptoms and which conditions preclude a diagnosis of ME/CFS. The definitions also differ in their conceptualisation of the cause and mechanisms of ME/CFS.

The 1994 CDC criteria, sometimes called the Fukuda criteria, require six months of persistent or relapsing fatigue for diagnosis, as well as the persistent presence of four out of eight other symptoms. While used frequently, the Fukuda criteria have limitations: PEM is not mandatory and originally symptoms only had to be “present”, rather than of at least moderate severity.

The Canadian Consensus Criteria, another commonly used criteria set, were developed in 2003. In addition to PEM and sleep problems, pain and neurological or cognitive issues are required for diagnosis. Furthermore, three categories of symptoms are defined (orthostatic, thermal instability and immunological). At least one symptom in two of these categories needs to be present. People diagnosed under the CCC have more severe symptoms compared to those diagnosed under the 1994 CDC criteria. Similarly, the International Consensus Criteria are stricter than the Fukuda criteria and select more severely ill people.

The 2015 criteria by the Institute of Medicine share significant similarities with the CCC but were developed to be easy to use for clinicians. Diagnosis requires fatigue, PEM, non-restorative sleep, and either cognitive issues (such as memory impairment) or orthostatic intolerance. Additionally, fatigue must persist for at least 6 months, should substantially impair activities in all areas of life and have a clearly defined onset. In 2021, NICE revised its criteria based on the IoM criteria. The updated criteria require fatigue, PEM, non-restorative sleep, and cognitive difficulties persisting for at least 3 months.

Separate diagnostic criteria have been developed for children and young people with ME/CFS, and criteria for adults have been altered to be suitable to children too. Criteria for children often require a shorter symptom duration. For example, the CCC definition only requires three months of persistent symptoms in children compared to six months for adults. NICE requires only four weeks of symptoms to suspect ME/CFS in children, compared to six weeks in adults. Exclusionary diagnoses also differ: for instance, children and teenager may have anxiety related to school attendance which could explain symptoms.

Differential diagnosis

Certain medical conditions have similar symptoms as ME/CFS and should be evaluated before a diagnosis of ME/CFS can be confirmed. While alternative diagnoses are explored, advice can be given on symptom management, to avoid delays in care. Post-exertional malaise often acts as a distinguishing feature of ME/CFS. A diagnosis of ME/CFS is only confirmed after six months of symptoms, to exclude acute medical conditions or problems related to lifestyle, which may resolve within that time frame.

Examples of possible differential diagnoses span a large set of specialties, and depend on patient history. Examples are infectious diseases (such as Epstein–Barr virus, HIV infection, tuberculosis, Lyme disease), neuroendocrine disorder (such as diabetes, hypothyroidism, Addison's disease, adrenal insufficiency), blood disorders (such as anemia) and some cancers. Various rheumatological and auto-immune diseases may also have overlapping symptoms with ME/CFS, such as Sjögren's syndrome, lupus and arthritis. Furthermore, evaluation of psychiatric diseases (such as depression, substance use disorder and anorexia nervosa) and neurological disorders (such as obstructive sleep apnea, narcolepsy, Parkinson's, multiple sclerosis, craniocervical instability) may be warranted. Finally, sleep disorders, coeliac disease, connective tissue disorders and side effects of medications may also explain symptoms.

Joint and muscle pain without swelling or inflammation is a feature of ME/CFS, but is more associated with fibromyalgia. Modern definitions of fibromyalgia not only include widespread pain, but also fatigue, sleep disturbances and cognitive issues, making the two syndromes difficult to distinguish. The two are often co-diagnosed. Ehlers–Danlos syndromes (EDS) may also have similar symptoms.

Like with other chronic illnesses, depression and anxiety co-occur frequently with ME/CFS. Depression may be differentially diagnosed from ME/CFS by feelings of worthlessness, the inability to feel pleasure, loss of interest and/or guilt; and the absence of bodily symptoms such autonomic dysfunction, pain, migraines or post-exertional malaise.

Management

There is no approved drug treatment or cure for ME/CFS, although some symptoms can be treated or managed. The CDC recommends a strategy treating the most disabling symptom first, and the NICE guideline specifies the need for shared decision-making between patients and medical teams. Clinical management varies widely, with many patients receiving combinations of therapies.

Pacing, or managing one's activities to stay within energy limits, can reduce episodes of post-exertional malaise. Addressing sleep problems with good sleep hygiene, or medication if required, may be beneficial. Chronic pain is common in ME/CFS, and the CDC recommends consulting with a pain management specialist if over-the-counter painkillers are insufficient. For cognitive impairment, adaptations like organizers and calendars may be helpful.

Symptoms of severe ME/CFS may be misunderstood as neglect or abuse during well-being evaluations, and NICE recommends that professionals with experience in ME/CFS should be involved in any type of assessment for safeguarding.

Co-occurring conditions that may interact with and worsen ME/CFS symptoms are common, and treating these may help manage ME/CFS. Commonly diagnosed ones include fibromyalgia, irritable bowel syndrome, allergies, and chemical sensitivities. The debilitating nature of ME/CFS can cause depression, anxiety or other psychological problems, which should be treated accordingly.

Pacing and energy envelope

Pacing, or activity management, is a management strategy based on the observation that symptoms tend to increase following mental or physical exertion. It was developed for ME/CFS in the 1980s, and is now commonly used as a management strategy in chronic illnesses and in chronic pain.

Its two forms are ''symptom-contingent pacing'', in which the decision to stop (and rest or change an activity) is determined by self-awareness of an worsening of symptoms, and ''time-contingent pacing'', which is determined by a set schedule of activities that a patient estimates they can complete without triggering post-exertional malaise (PEM). Thus, the principle behind pacing for ME/CFS is to avoid overexertion and an exacerbation of symptoms. It is not aimed at treating the illness as a whole. Those whose illness appears stable may gradually increase activity and exercise levels, but according to the principle of pacing, must rest or reduce their activity levels if it becomes clear that they have exceeded their limits.

Energy envelope theory, consistent with pacing, states that patients should stay within, and avoid pushing through, the ''envelope'' of energy available to them, so as to reduce the post-exertional malaise "payback" caused by overexertion. This may help them make "modest gains" in physical functioning. Use of a heart-rate monitor with pacing to monitor and manage activity levels is recommended by a number of patient groups, and the CDC considers it useful for some individuals to help avoid post-exertional malaise.

Several studies have found energy envelope theory to be a helpful management strategy, noting that it reduces symptoms and may increase the level of functioning in ME/CFS. A 2023 review of pacing studies stated that while most trials found a positive effects, studies were typically small and rarely included a way to tell if patients implemented pacing well. It said that until large RCTs are undertaken, the literature base is insufficient to inform treatment practises.

Exercise

Stretching, movement therapies, and toning exercises are recommended for pain in people with ME/CFS. In many chronic illnesses, aerobic exercise is beneficial, but in chronic fatigue syndrome, the CDC does not recommend it. The CDC states:Short periods of low-intensity exercise to improve stamina may be possible in a subset of people with ME/CFS. Exercise should only be attempted after pacing has been implemented effectively. The amount of exercise should be varied based on the symptom severity of each day, to avoid PEM.

Graded exercise therapy (GET), a proposed treatment for ME/CFS which assumes deconditioning a fear of activity plays an important role in maintaining the illness, is no longer recommended for people with ME/CFS. Reviews of GET either see weak evidence of a small to moderate effect or no evidence of effectiveness. There are reports of serious adverse effects from GET and few clinical trials contained enough detail about adverse effects.

Counseling

Chronic illness often impacts mental health. Psychotherapy may help people with ME/CFS manage the stress of being ill, apply self-management strategies for their symptoms, and cope with physical pain. Cognitive behavioral therapy (CBT) may be offered to people with a new ME/CFS diagnosis to give them tools to cope with the disease and help with rehabilitation. A mindfullness approach is sometimes also chosen.

If sleep problems remain after implementing sleep hygiene routines, cognitive behavioral therapy for insomnia can be offered. Family sessions may be useful to educate people close to those with ME/CFS about the illness' severity. Depression or anxiety resulting from ME/CFS is common, and CBT may be a useful treatment.

In the past, a form of CBT was offered that assumed the illness was maintained due to unhelpful beliefs about the illness and unhelpful coping behavior avoiding activity. According to this model, their fear of triggering symptoms can prolong the condition, creating a harmful cycle of avoiding activity and becoming less physically active. This model has been criticized as lacking evidence and being at odds with the biological changes associated with ME/CFS. NICE removed their recommendation for this form in 2021.

Diet and nutrition

A proper diet is a significant contributor to the health of any individual. Medical consultation about diet and supplements is recommended for persons with ME/CFS. Persons with ME/CFS may also benefit from nutritional support if deficiencies are detected by medical testing. However, nutritional supplements may interact with prescribed medication.

Bowel issues are a common symptom of ME/CFS. For some, eliminating certain food groups, such as caffeine, alcohol or dairy, can alleviate symptoms. People with severe ME/CFS may have significant trouble getting nutrition. Intravenous feeding (via blood) or tube feeding may be necessary to address this, or to address electrolyte imbalances.

Aids and adaptations

People with moderate to severe ME/CFS may benefit from home adaptations and mobility aids, such as wheelchairs, disability parking, shower chairs, or stair lifts. To manage sensitivities to environmental stimuli, these stimuli can be limited. For instance, the use of perfume can be discouraged, or the patient can use an eye mask or earplugs.

Prognosis

Information on the prognosis of ME/CFS is limited, and the course of the illness is variable. Complete recovery, partial improvement, and worsening are all possible, but full recovery is rare. Symptoms generally fluctuate over days, weeks, or longer periods, and some people may experience periods of remission. Overall, "many will need to adapt to living with ME/CFS."

An early diagnosis may improve care and prognosis. Factors that may make the disease worse over days but also over longer time periods are physical and mental exertion, a new infection, sleep deprivation, and emotional stress. Some people who improve need to manage their activities in order to prevent relapse. Children and teenagers are more likely to recover or improve than adults. For instance, a study in Australia among 6- to 18-year olds found two thirds reported recovery after ten years, and that the typical duration of illness was 5 years.

The effect of ME/CFS on life expectancy is poorly studied, and evidence is mixed. A larger study on the topic found no increase in all-cause mortality due to ME/CFS.

Epidemiology

Reported prevalence rates vary widely depending on how ME/CFS is defined and diagnosed. Based on the 1994 CDC diagnostic criteria, the global prevalence rate for CFS is 0.89%. In comparison, estimates using the 1988 CDC "Holmes" criteria and 2003 Canadian criteria for ME produced an incidence rate of only 0.17%.

As of 2015, between 836,000 and 2.5 million Americans were estimated to have ME/CFS, with 84–91% of these being undiagnosed.In England and Wales, over 250,000 people are estimated to be affected. The worldwide prevalence is 17 and 24 million. These estimates are based on data before the COVID-19 pandemic. It is likely that numbers have increased as a large share of people with Long COVID meet the diagnostic criteria of ME/CFS. A 2021–2022 CDC survey found that 1.3% of adults in the United States, or 3.3 million, had ME/CFS.

Females are diagnosed about 1.5 to 2.0 times more often with ME/CFS than males. An estimated 0.5% of children have ME/CFS, and more adolescents are affected with the illness than younger children. The incidence rate according to age has two peaks, one at 10–19 and another at 30–39 years, and the rate of prevalence is highest between ages 40 and 60.

History

From 1934 onwards, there were multiple outbreaks globally of an unfamiliar illness, initially mistaken for polio. A 1950s outbreak at London's Royal Free Hospital led to the term "benign myalgic encephalomyelitis" (ME). Patients displayed symptoms such as malaise, sore throat, pain and signs of nervous system inflammation. While its infectious nature was suspected, the exact cause remained elusive. The syndrome appeared in sporadic as well as epidemic cases.

In 1970, two UK psychiatrists proposed that these ME outbreaks were psychosocial phenomena, suggesting mass hysteria or altered medical perception as potential causes. This theory, though challenged, sparked controversy and cast doubt on ME's legitimacy in the medical community.

Melvin Ramsay's subsequent research emphasized ME's disabling nature, prompting the removal of "benign" from the name and the establishment of diagnostic criteria in 1986. These criteria included the tendency of muscles to tire after minor effort and taking multiple days to recover, high symptom variability, and chronicity. Despite Ramsay's efforts and a UK report acknowledging ME as not psychological, skepticism persisted within the medical field, leading to limited research.

In the United States, Nevada and New York State saw outbreaks of what appeared similar to mononucleosis in the middle of the 1980s. People suffered from "chronic or recurrent fatigue", among a large number of other symptoms. The initial link of elevated antibodies to the Epstein–Barr virus had the illness acquire the name "chronic Epstein–Barr virus syndrome. The CDC renamed it chronic fatigue syndrome (CFS), as a viral cause could not be confirmed in studies. An initial case definition of CFS was defined in 1988; the CDC published new diagnostic criteria in 1994, which became widely referenced.

In the 2010s, ME/CFS gained increasing recognition from health professionals and the public. Two reports proved key in this shift. In 2015, the Institute of Medicine produced a report with new diagnostic criteria, which described ME/CFS as a "serious, chronic, complex systemic disease". The US National Institutes of Health subsequently published their Pathways to Prevention report, which gave recommendations on research priorities.

Society and culture

Naming

Many names have been proposed for the illness. Currently, the most commonly used are "chronic fatigue syndrome", "myalgic encephalomyelitis", and the umbrella term "myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)". Reaching consensus on a name is challenging because the cause and pathology remain unknown.

Many patients object to the term "chronic fatigue syndrome". They consider the term simplistic and trivialising, which in turn prevents the illness from being taken seriously. At the same time, there are also issues with the use of "myalgic encephalomyelitis", as there is only limited evidence of brain inflammation implied by the name. The umbrella term ME/CFS would retain the better-known phrase CFS without trivialising the disease, but some people object to this name too as they see CFS and ME as distinct illnesses.

A 2015 report from the Institute of Medicine recommended the illness be renamed "systemic exertion intolerance disease", (SEID), and suggested new diagnostic criteria, proposing post-exertional malaise (PEM), impaired function, and sleep problems are core symptoms of ME/CFS. While the new name was not widely adopted, the diagnostic criteria were taken over by the CDC. Like CFS, SEID only focuses on a single symptom and patient opinions have generally been negative.

Economic and social impact

ME/CFS negatively impacts people’s social lives and relationships. Stress can be compounded by disbelief in the illness from the support network, who can be sceptical due to subjective nature of diagnosis. Many people with the illness feel socially isolated, and thoughts of suicide are high especially in those without a supportive care network. Compared to other patient groups, people with ME/CFS engage more in peer-to-peer support online.

For children, normal development becomes interrupted due to ME/CFS, as they increasingly rely on their family for assistance, rather than become more independent with age. Unpaid carers also face challenges. Caring for somebody with ME/CFS can be a full-time role, and the stress of caregiving is made worse by the lack of effective treatments and by the historical biases.

Economic costs due to ME/CFS are "significant". A 2021 paper by Leonard Jason and Arthur Mirin estimated the impact in the US to be $36–51 billion per year, or $31,592 to $41,630 per person, considering both lost wages and healthcare costs. The CDC estimated direct healthcare costs alone at $9–14 billion annually. A 2017 estimate for the annual economic burden in the United Kingdom was £3.3 billion.

Advocacy

12 May is designated as ME/CFS International Awareness Day. The goal of the day is to raise awareness among the public and health care workers on diagnosis and treatment of ME/CFS. It was chosen because it is the birthday of Florence Nightingale, who had an unidentified illness appearing similar to ME/CFS.

Advocacy and research organisations include MEAction, Open Medicine Foundation and the Solve ME/CFS Initiative in the US, the ME Association in the UK, and the European ME Coalition.

Doctor–patient relations

The NAM report refers to ME/CFS as "stigmatized", and the majority of patients report negative healthcare experiences. These patients may feel that their doctor inappropriately calls their illness psychological or doubts the severity of their symptoms. They may also feel forced to prove that they are legitimately ill. Some may be given outdated treatments that provoke symptoms or assume their illness is due to unhelpful thoughts and deconditioning. In a 2009 survey, only 35% of patients considered their physicians experienced with CFS and only 23% thought their doctors knew enough to treat it.

Doctors may have trouble managing an illness that lacks a clear cause or treatment. Clinicians may be unfamiliar with ME/CFS, as it is often not covered in medical school. Due to this unfamiliarity, people may go undiagnosed for years, or be misdiagnosed with mental conditions. A substantial portion of doctors are uncertain about how to diagnose or manage chronic fatigue syndrome. In a 2006 survey of GPs in southwest England, 75% accepted it as a "recognisable clinical entity", but 48% did not feel confident in diagnosing it, and 41% in managing it.

Controversy

ME/CFS is a contested illness, with debates mainly revolving around the cause of the illness and treatments. Historically, there was a heated discussion whether the condition was psychological or neurological. Professionals who subscribed to the psychological model had frequent conflicts with patients, who believed their illness to be organic. While ME/CFS is now generally believed to be a multisystem neuroimmune condition, a subset of professionals still see the condition as psychosomatic, or an "illness-without-disease".

The possible role of chronic viral infection in ME/CFS has been a subject of disagreement. One viral study caused considerable controversy by establishing a causal relationship between ME/CFS and the retrovirus XMRV. Some with the illness began taking AIDS drugs, and national blood supplies were suspected to be tainted with the retrovirus. After several years of study, the XMRV findings were determined to be the result of contamination of the testing materials.

Treatments based on behavioural and psychological models of the illness have also been the subject of much contention. The largest clinical trial on behavioural interventions, the 2011 PACE trial, concluded that graded exercise therapy and CBT are moderately effective. The trial drew heavy criticism. The study authors changed the definition of recovery during the trial, leading to more recovered patients by the end of the trial. After the change, some patients even met the criteria at the intervention's outset. A reanalysis under the original protocol showed no significant difference in recovery rate between treatment groups and controls.

Research funding

Historical research funding for ME/CFS has been far below that of comparable diseases. In a 2015 report, the U.S. National Academy of Sciences called it "remakabl how little funding there had been for research into causes, mechanisms and treatment. Lower funding levels have led to a smaller number and size of studies. In addition, drug companies have invested very little in the disease.

The U.S. National Institutes of Health (NIH) is the largest biomedical funder worldwide. Using rough estimates of disease burden, a study found NIH funding for ME/CFS was only 3% to 7% of the average disease per healthy life year lost between 2015 and 2019. Worldwide, multiple sclerosis, which affects fewer people and results in disability no worse than ME/CFS, received 20 times as much funding between 2007 and 2015.

Multiple reasons have been proposed for the low funding levels. Diseases for which society "blames the victim" are frequently underfunded. This may explain why a severe lung disease often caused by smoking receives low funding per healthy life year lost. Similarly for ME/CFS, the historical belief that it is caused by psychological factors, may have contributed to lower funding. Gender bias may also play a role; the NIH spends less on diseases which predominantly affect women in relation to disease burden. Less well funded research areas may also struggle competing with more mature areas of medicine for the same grants.

Notable cases

In 1989, ''The Golden Girls'' (1985–1992) featured chronic fatigue syndrome in a two-episode arc, "Sick and Tired: Part 1" and "Part 2", in which protagonist Dorothy Zbornak, portrayed by Bea Arthur, after a lengthy battle with her doctors in an effort to find a diagnosis for her symptoms, is finally diagnosed with CFS. American author Ann Bannon had CFS. Laura Hillenbrand, author of the popular book ''Seabiscuit'', has struggled with CFS since age 19.

Research

Research into ME/CFS seeks to find a better understanding of the disease's causes, biomarkers to aid in diagnosis, and treatments to relieve symptoms. The emergence of long COVID has sparked increased interest in ME/CFS, as the two conditions may share pathology, and a treatment for one may treat the other.

Pathophysiology

Recent research suggests dysfunction in many biological processes. These changes may share a common cause, but the true relationship between them is currently unknown. Metabolic areas of interest include disruptions in amino acid metabolism, the TCA cycle, ATP synthesis, and potentially increased lipid metabolism. Other research has investigated immune dysregulation and its potential connections to mitochondrial dysfunction. People with ME/CFS may have abnormal gut microbiota, which has been proposed to affect mitochondria or nervous system function.

Many biomarkers for ME/CFS have been proposed, but there is no consensus on a biomarker as of yet. The search for biomarkers is complicated due to the historical dominance of the broad Fukuda criteria. Studies on biomarkers have often been too small to draw robust conclusions. NK cells have been identified as an area of interest for biomarker research, as they show consistent abnormalities. Other proposed markers include electrical measurements of blood cells and a combination of immune cell death rate and function.

Several small studies have investigated the genetics of ME/CFS, but none of their findings have been replicated. A larger study, DecodeME, is currently underway in the United Kingdom.

Treatments

Various drug treatments for ME/CFS are being explored. The types of drugs under investigation often target the nervous system, the immune system, autoimmunity, or pain directly. More recently, there has been a growing interest in drugs targeting energy metabolism.

One of the drugs studied for use in ME/CFS is rintatolimod. In several clinical trials of ME/CFS, the treatment has shown a small reduction in symptoms, but improvements were not sustained after discontinuation. Rintatolimod has been approved in Argentina. Low-dose naltrexone, which works against neuro-inflammation, is being studied as of 2023. Rituximab, a drug that depletes B cells, was studied and found to be ineffective. Other options targetting auto-immunity are immune absorption, whereby a large set of (auto)antibodies is removed from the blood.

Challenges

ME/CFS affects multiple bodily systems, varies widely in severity, and fluctuates over time, creating heterogeneity within patient groups and making it very difficult to identify a singular cause. This variation may also cause treatments that are effective for some to have no effect or a negative effect in others. Dividing people with ME/CFS into subtypes may help manage this heterogeneity.

The existence of multiple diagnostic criteria, and variations in how scientists apply them, complicate comparisons between studies. Some definitions, like the Oxford and Fukuda criteria, may fail to distinguish between chronic fatigue in general and ME/CFS, which requires PEM in modern definitions. Definitions also vary in which co-occurring conditions preclude a diagnosis of ME/CFS.

References

External links

{{DEFAULTSORT:Chronic Fatigue Syndrome

Immune system disorders
Neurological disorders
Syndromes of unknown causes